肿瘤细胞化疗后99Tcm-DTPA-DG摄取研究

 目的 探讨 99Tcm 标记二乙三胺五乙酸葡糖胺（99Tcm- DTPA-DG）在恶性肿瘤化疗早期疗效监测中的应用价值。 方法 将体外培养肺癌细胞 A549、结肠癌细胞 HT-29 和乳腺癌细胞 MCF-7 各分为加入化疗药物的化疗组和不加化疗药物的阴性对照组，所选化疗药物分别为顺铂、5-氟尿嘧啶、紫杉醇。化疗药作用 6 h 后，荧光倒置显微镜下观察各化疗组和对照组细胞形态变化，并行磷脂结合蛋白 V（AV）/ 碘化丙啶（PI）双标记染色，采用流式细胞仪检测各组细胞的凋亡率，化疗药作用 4 h 后，各化疗组和对照组分别加入 37 MBq/L 的 99Tcm-DTPA-DG 各 0.1 ml，反应 2 h，用 γ 测量仪检测 99Tcm-DTPA-DG 摄取率。 结果 经单用化疗药作用后，3 种肿瘤细胞在荧光倒置显 微镜下观察均可见凋亡小体形成。流式细胞仪检测也均 出现凋亡峰。化疗组和对照组的凋亡率肺癌细胞分别为 43.60% ± 2.82% 和 1.21% ± 0.15%，结肠癌细胞分别为 32.42% ± 2.02% 和 2.04% ± 0.23%，乳腺癌细胞分别为 52.33% ± 2.72% 和 1.31% ± 0.10%，差异均有统计学意义 （P < 0.01）。γ 测量仪检测显示 3 种肿瘤细胞化疗组 99Tcm-DTPA-DG 摄取率均明显低于对照组（肺癌细胞分别为 0.44% ± 0.02%、0.79% ± 0.12%，结肠癌细胞分别为 0.35% ± 0.13%、0.58% ± 0.23%，乳腺癌细胞分别为 0.28% ± 0.05%、0.65% ± 0.18%，均P < 0.01）。结论 99Tcm-DTPA-DG 是一种可望用于肿瘤化疗效果早期评估的靶向分子显像剂。     

经动脉化疗栓塞兔VX2肝癌后早期肿瘤细胞凋亡

目的　研究介入治疗兔VX2肝癌肿瘤细胞凋亡的早期动态改变 .方法　建立 2 7只新西兰大白兔VX2肝癌模型 ,随机分成肝动脉化疗栓塞组 (Transarterialchemoembolization ,TACE)、灌注化疗组 (Transarterialinfusion ,TAI)、灌注肝素生理盐水组 (对照组 ,Control) ,每组各 9只 .介入治疗后每组再随机分成 3个亚组 ,每亚组 3只 .在治疗后第2 4、72、12 0小时分别处死 3组中一亚组 ,取材肿瘤生长活跃的外带组织用流式细胞仪AnnexinV和PI双标记法定量检测细胞凋亡 ,组织病理切片苏木精 -伊红染色 (HE染色 )和甲基绿 -派洛宁染色 (MG -P染色 )光镜下形态学方法观察不同时间肿瘤细胞的凋亡变化 .结果　TACE、TAI、Control组在治疗后 2 4、72、12 0小时流式细胞仪法定量检测肿瘤细胞凋亡比率分别为 11.4 4± 2 .15、10 .99± 1.74、6 .0 0± 0 .5 8,5 .84± 0 .6 8、4 .6 5± 0 .11、2 .88± 1.2 3和 2 .80± 0 .15、2 .19± 1.6 9、2 .5 1± 2 .13.TACE、TAI、Control组凋亡在各时间点均有显著差异 (p <0 .0 1) ,TACE组 2 4、72小时的凋亡明显高于 12 0小时 (p <0 .0 5 ) .TACE组诱导的肿瘤细胞凋亡比率明显高于TAI、Control组 ;TACE组诱导的肿瘤细胞早期凋亡比率随时间呈下降趋势 ,在 12 0小时凋亡仍明显高于其     

肿瘤抑制剂GA对SH-SY5Y细胞凋亡的影响及分子机制研究

为了探讨HSP90特异的功能抑制剂geldanamycin(GA)能否用于神经母细胞瘤的临床治疗 ,通过检测未分化的和全反式维甲酸 (RA)诱导分化的神经母细胞瘤SH SY5Y细胞在不同浓度GA处理后的细胞存活率 ,发现GA呈剂量依赖性诱导SH SY5Y细胞凋亡 ,但是分化细胞对同样剂量的GA不是很敏感 [细胞存活率依次为 (82 0±6 0 ) %比较 (6 5 0± 3 0 ) % ,P <0 0 2 ;(6 7 9± 3 1) %比较 (4 3 4± 3 9) % ,P <0 0 3;(4 3± 0 8) %比较 (0 4±0 1) % ,P <0 0 5 ]。Western印迹分析和免疫荧光实验显示 ,GA能抑制细胞中c Jun和c Fos的表达 ,并且GA剂量越高 ,其抑制越明显 ;同时GA也诱导了p5 3的核聚集。与未分化细胞相比 ,在相同剂量GA处理后分化细胞中c Jun和c Fos的表达均比未分化细胞略高 ;但是分化细胞中p5 3的核聚集却不如前者明显。提示未分化细胞对同样剂量的GA比分化细胞更敏感 ,可能与分化细胞能抵抗GA引起的c Jun、c Fos的降低以及p5 3的核聚集有关。     

大蒜素诱导人肝癌BEL—7402细胞凋亡

目的　探讨大蒜素诱导人肝癌BEL 740 2细胞凋亡作用。　方法　MTT法检测大蒜素对BEL 740 2细胞的生长抑制作用 ,光镜、电镜、流式细胞术观察大蒜素诱导BLE 740 2细胞凋亡作用。　结果　 10、2 0、40ml L大蒜素皆能抑制BEL 740 2细胞生长 ,其抑制作用与剂量、作用时间呈正相关。 6 0mg L大蒜素作用 3h ,BEL 740 2细胞出现典型凋亡形态学变化 :细胞体积缩小 ,微绒毛消失 ,染色质浓聚、边集、裂解 ,细胞表面凸起多个小泡或小球状小体 ,凋亡细胞拒染台盼蓝等。台盼蓝染色计数对照组凋亡率 2 0 2± 0 37% ,诱导组凋亡率 78 48± 3 15 % ;流式细胞分析对照组凋亡率 1 78± 0 48% ,诱导组凋亡率 74 0 7± 3 94% ,对照组诱导前时G0 /G1 、S、G2 /M期细胞分别为47 6 6± 2 72 % ,2 2 0 6± 2 0 4% ,30 2 5± 3 78% ,皆低于 74 0 7± 3 94%。　结论　大蒜素诱导人肝癌BEL 740 2细胞凋亡 ,其诱导凋亡效果明显 ,并推测大蒜素诱导BEL 740 2细胞可能自细胞周期不同分期多点启动凋亡     

Ki-67、早期凋亡相关蛋白M30在子宫内膜癌的表达及其与预后的关系

目的　探讨子宫内膜癌增殖抗原Ki 6 7及早期凋亡相关蛋白M 30 (M30CytoDEATH ,细胞角蛋白 18)的表达与其生物学行为间的关系。方法　采用免疫组织化学链霉素抗生物素蛋白 过氧化物酶 (SP)法 ,分别检测了 79例子宫内膜癌Ki 6 7及M30蛋白的表达情况。结果　 79例子宫内膜癌中 ,不同病理学分级间Ki 6 7平均指数分别为 :G1:2 0 4 8± 14 86 ;G2 :2 4 12± 14 4 2 ;G3:38 84± 11 88。不同临床分期间Ki 6 7平均指数分别为 :Ⅰ期 :2 0 6 5± 13 5 6 ;Ⅱ期 :2 6 92± 14 71;Ⅲ期 :35 14± 14 70。不同病理学分级间M30蛋白平均指数分别为 :G1:1 0 3± 1 4 2 ;G2 :1 0 3± 1 6 4 ;G3:1 94± 1 2 0。不同临床分期间M30蛋白平均指数分别为 :Ⅰ期 :0 30± 0 5 8;Ⅱ期 :1 6 6± 1 74 ;Ⅲ期 :2 0 7± 1 6 2。研究结果还显示子宫内膜癌M30指数随Ki 6 7指数增高而增高 ,它们之间呈显著正相关。生存分析表明 ,Ki 6 7指数≥ 30、M30指数≥ 2的患者比Ki 6 7指数≤ 10、M 30指数≤ 1的患者生存率显著降低。结论　Ki 6 7指数、M 30指数越高 ,子宫内膜癌生物学行为越差 ,患者预后也越差。Ki 6 7指数、M 30指数较高的患者 ,生存率显著降低。高分化子宫内膜癌 (G1)中 ,Ki 6 7指数≥30、M30指数≥ 2者可能提示患者预     

VEGF-C及其受体Flt4在乳腺癌转移中的作用

目的　探讨VEGF C/VEGFR 3(Flt4)在乳腺癌转移中的作用和意义。方法　采用免疫组化S P法检测 10 1例乳腺癌组织中VEGF C、Flt4的表达。结果　 10 1例乳腺癌组织VEGF C阳性率为 93 1%(94/10 1) ,Flt4阳性率为 86 1%(87/10 1) ,且VEGF C与Flt4表达呈正相关。VEGF C阳性指数在转移组 (6 1 89± 17 79)高于未转移组 (44 2 8± 17 87) (P <0 0 5 )。随着癌细胞VEGF C表达强度增强 ,Flt4阳性脉管数也随之增加 ,各组间差异均有显著性 (P <0 0 1)。乳腺癌中Flt4阳性脉管数在淋巴结转移组 (15 5 5± 3 6 3)高于未转移组 (10 71± 2 90 ) (P <0 0 5 )。结论　乳腺癌细胞高水平表达VEGF C、Flt4,两者表达呈正相关。Flt4阳性脉管数与淋巴结转移密切相关。     

胃黏膜相关淋巴组织型淋巴瘤细胞凋亡和bcl—2、p53蛋白表达

目的 :探讨胃黏膜相关淋巴组织型 (MALT)淋巴瘤中细胞凋亡特点及其与bcl 2、p5 3基因蛋白表达的关系。 方法 :应用TdT酶介导生物素化dUTP缺口末端标记 (TUNEL)技术 ,显示肿瘤凋亡细胞 ,免疫组织化学S P法显示bcl 2、p5 3基因蛋白表达。结果 :低度恶性 ,低高混合恶性 ,以及高度恶性组肿瘤细胞凋亡率平均分别为 (0 2 5± 0 12 ) %、(0 46± 0 2 4) %及 (1 32± 0 35 ) % ;而三组bcl 2阳性率分别为 83%、61 6 %及 43 7%。高度恶性组与低度恶性组bcl 2阳性率及凋亡发生率均差异有显著性 (P <0 0 5 ) ;bcl 2表达与凋亡率呈显著负相关 (P <0 0 5 ) ;86例肿瘤组织中 ,p5 3阳性者 2 7例 (30 % ) ,其中低度恶性组 3例 ,混合恶性组 3例 ,高度恶性组 2 1例。高度恶性组 p5 3阳性率高于其余两组。p5 3表达与bcl 2表达著负相关 (P <0 0 5 )。结论 :在胃MALT淋巴瘤中 ,随着组织学分级的提高 ,凋亡细胞显著增多 ,凋亡在肿瘤发生发展转化中起重要作用。p5 3和bcl 2均为重要的凋亡调控基因 ,在胃MALT淋巴瘤从低度恶性到高度恶性的转化中 ,p5 3和bcl 2基因可能起重要作用。     

P38激酶介导胆红素诱导的SHSY5Y细胞凋亡

观察P38激酶在胆红素诱导神经细胞凋亡中的作用 ,探讨参与此过程的信号转导通路。将胆红素 (2× 1 0 -2g L)直接作用于体外培养的人神经母细胞瘤细胞系SHSY5Y ,利用Hochest332 58染色在荧光显微镜下观察细胞核的形态是否发生凋亡样改变 ;用P38激酶抑制剂SB2 0 3580预处理细胞后 ,在倒置光显微镜下观察胆红素作用不同时间细胞形态的变化及存活情况 ;利用流式细胞仪检测细胞凋亡率的改变。结果显示SHSY5Y细胞经胆红素作用后细胞核出现典型的凋亡样改变 ;细胞经SB2 0 3580预处理 1h ,胆红素作用 3h后凋亡率为 (1 2 1± 2 4) % ,对照组为(1 9 4± 2 7) % ;4h后凋亡率为 (39 3± 4 8) % ,对照组为 (66 2± 5 2 ) % ,差异有显著性意义 (P <0 0 1 )。提示P38激酶参与了胆红素诱导SHSY5Y细胞凋亡的信号转导过程     

郑氏植物蛋白对乳腺癌及其癌前病变患者PBL的刺激作用及其意义

目的 :研究郑氏植物蛋白 (Zheng’splant protein ,ZPP)对淋巴细胞的刺激作用及其在乳腺癌早期诊断与治疗中的应用价值。方法 :采用3 H TdR掺入法测定人外周血淋巴细胞(PBL) )的增殖反应。用流式细胞仪测定ZPP对T淋巴细胞CD3+ 、CD4 + 和CD8+ 抗原表达的调节作用。结果 :ZPP对乳腺癌及其前期病变患者PBL有较强的刺激作用 (SI分别为3.0 0± 1.4 5和 2 .5 3± 0 .80 ) ,明显高于对正常对照组和乳管上皮轻度增生患者PBL的刺激指数 (SI分别为 1.0 6± 0 .17和1.18± 0 .19) (P <0 .0 1)。而PHA对各组PBL的增殖反应均有不同程度的刺激作用 ,但各组间无明显差异 (P >0 .0 5 ) .经ZPP刺激后的PBL中CD3+ 、CD4 + 和CD8+ 细胞均发生增殖反应 ,其中CD4 + 和CD8+ 者更为明显。结论 :ZPP可选择性刺激乳腺癌及其前期病变患者的PBL中T细胞发生增殖反应 ,此作用有可能用于乳腺癌的早期诊断与治疗中     

肺鳞状细胞癌中死亡相关蛋白激酶的表达

目的　检测肺鳞状细胞癌中死亡相关蛋白激酶 (DAP K)mRNA表达及细胞凋亡 ,探讨DAP K与细胞凋亡的关系及其在肺鳞状细胞癌发生、发展中的作用。方法　用原位分子杂交法检测 6 0例肺鳞状细胞癌、9例癌旁肺组织DAP KmRNA表达 ;用原位末端标记TUNEL法检测相应组织中细胞凋亡 ,计算凋亡指数 (AI)。结果　肺鳞状细胞癌的DAP KmRNA阳性表达率为 4 6 7% ,癌旁肺组织为 6 7 7% ,其阳性率高于肿瘤组织 (P <0 0 1 )。在肺鳞状细胞癌中 ,高分化癌DAP KmRNA阳性率为 70 % ,低分化癌为 2 3 3% ,高分化癌的DAP KmRNA阳性率高于低分化癌 (P <0 0 1 )。肺鳞状细胞癌的细胞AI为(0 6 72 8± 0 4 2 6 1 ) % ,癌旁肺组织中支气管肺泡上皮细胞AI为 (1 0 2 89± 0 2 4 33) % ,癌旁肺组织的AI高于肿瘤组织 (P<0 0 1 )。在肺鳞状细胞癌中 ,高分化癌的AI为 (0 5 82 3± 0 1 92 2 ) % ,低分化癌为 (0 4 4 6 0± 0 1 92 5 ) % ,高分化癌的AI高于低分化癌 (P <0 0 1 )。DAP KmRNA呈阳性表达的肺癌 ,其AI为 (0 5 31 7± 0 2 0 97) % ;DAP KmRNA呈阴性者 ,其AI为 (0 4 872± 0 1 91 8) % ,两组间差异有显著性 (P <0 0 5 )。在连续切片上 ,DAP KmRNA阳性细胞的分布区域与凋亡阳性细胞的分布相似。DAP KmRNA呈阳性表达     

Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors

Background

Accurate pathological assessment of breast specimens after NACT is crucial. It is beneficial to determine the treatment efficacy and predict prognosis. So we should explore the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors, which about survival analysis and disease free survival involved, which was one part of contributing for evaluating in terms of global survival and disease free survival.

Prognostic significance of glutathione S-transferase-pi in invasive breast cancer.

Glutathione S-transferase pi (GST-pi), a Phase II detoxification enzyme, has recently been implicated in protection against apoptosis. Expression of GST-pi and Bcl-2 protein, an established apoptosis marker, was analyzed by immunohistochemistry in 116 cases of infiltrative ductal breast carcinomas in Singapore women. The markers were correlated with apoptosis detected by the TUNEL method and clinico-pathological parameters. There were 67 (58%) GST-pi-positive breast tumors and 43 (37%) Bcl-2-positive tumors. In a large proportion of GST-pi-positive/Bcl-2-positive tumors, there was a distinct accumulation of the GST-pi enzyme within the nucleus of cancer cells when examined by double immunofluorescence labeling under confocal microscopy. GST-pi immunoreactivity was not significantly correlated with any of the traditional histologic factors known to influence prognosis, whereas Bcl-2 overexpression was associated with reduced size of primary tumor (P =.021) and positive estrogen receptor status (P =.001). Univariate analysis revealed that GST-pi-positive, Bcl-2-positive, and lower histological grade tumors had decreased levels of apoptosis (P =.024, P =.011, and P =.029, respectively). However, multivariate analysis showed that histological grade and Bcl-2, but not GST-pi, immunoreactivity were correlated with apoptotic status. The Kaplan-Meier disease-free survival curves showed a significant difference between GST-pi-positive and GST-pi-negative breast cancer cases (P =.002). Disease-free survival in patients with GST-pi-positive tumors was also worse than that in patients with GST-pi-negative tumors in the group who had adjuvant chemotherapy (P =.04). In patients who were lymph node positive, GST-pi immunopositivity was found to influence disease-free survival. Recurrence of tumors was also significantly affected by GST-pi immunoreactivity (relative risk of 8.1). The findings indicate that GST-pi-positive tumors are more aggressive and have a poorer prognosis than do corresponding GST-pi-negative breast cancers.     

E-Cadherin在乳腺癌中的表达及其意义

目的：探讨Ｅ－Ｃａｄｈｅｒｉｎ表达与乳腺癌的分级、浸润，淋巴结转移及病人后的关系。方法．：采用免疫组化Ｓ－Ｐ方法对１０９例乳ａｄｈｅｒｉｎ表达进行研究。结果：乳腺癌Ｅ－Ｃａｄｈｅｒｉｎ表达阳笥纺为５２．３％，，其表达与肿瘤组织学类型无关。Ｅ－Ｃａｄｈｅｒｉｎ表达，阴性患者淋巴结转移率显著高于阳性者；Ｅ－Ｃａｄｈｅｒｉｎ阳性患者５年生存率比阳性者显著增高。结论：Ｅ－Ｃａｄｈｅｒｉｎ表达对估计乳腺癌淋     

诱生型一氧化氮合酶的变化在高胆固醇血症大鼠肾损害中的作用

目的:探讨高胆固醇血症大鼠肾组织诱生型一氧化氮合酶(iNOS)的变化与脂质肾损害的关系。方法:采用生化法检测血脂、尿蛋白、尿及肾皮质中一氧化氮含量,免疫组化法及逆转录—多聚酶链法检测肾组织中iNOS的表达强度及水平。TUNEL法检测肾组织中凋亡细胞。结果:8周时高脂组大鼠血清总胆固醇、低密度脂蛋白胆固醇、24h尿蛋白定量及尿一氧化氮量、肾皮质一氧化氮含量明显高于对照(P＜0.05)。肾皮质iNOSmRNA表达上调(P＜0.01)。肾皮质一氧化氮量与24h尿蛋白定量呈正相关(P＜0.05)。肾皮质iNOS积分光度与肾组织细胞凋亡指数呈正相关(P＜0.05)。肾组织细胞凋亡指数与24h尿蛋白含量呈正相关(P＜0.01)。结论:iNOS表达增强与脂质肾损害有关,可能通过引起细胞凋亡导致脂质肾损害。     

乳腺癌中凋亡与细胞增殖及Rb、bcl-2、c-myc蛋白表达的关系

目的：了解人乳腺癌中凋亡与细胞增殖的关系,以及与相关基因蛋白表达的关系及其预后意义。方法：用免疫组化ＬＳＡＢ法检测了９０例乳腺标本（包括１３例良性乳腺病变和７７例乳腺癌）中Ｒｂ、ｂｃｌ２和ｃｍｙｃ的蛋白表达;并计数了癌组织中的凋亡指数（ＡＩ,ＴＵＮＥＬ法）和有丝分裂指数（ＭＩ）。结果：ＡＩ与ＭＩ呈显著的正相关（ｒ＝０８１,Ｐ＜００１）;ＡＩ、ＭＩ和Ｒｂ蛋白表达与肿瘤大小和组织学分级有关,ＡＩ、ＭＩ低和ｂｃｌ２的高表达与５年生存率有关,ｃｍｙｃ的表达仅与组织学等级有关（Ｐ＜００５）;Ｒｂ表达与ＡＩ、ＭＩ均有关（Ｐ＜００１）,而ｂｃｌ２的表达仅与ＡＩ有关（Ｐ＜００５）。结论：乳腺癌中凋亡与细胞增殖和ｂｃｌ２表达有关,提示凋亡在具有不同生长潜能的亚群的克隆性选择中发挥重要作用。Ｒｂ与凋亡的关系提示细胞凋亡与细胞周期有关。     

LCL161联合Z-VAD-FMK对人乳腺癌细胞MCF-7和MDA-MB-231增殖的影响

目的:探讨第二个线粒体衍生的半胱氨酸蛋白酶激动剂小分子(Smac)类似物LCL161联合天冬氨酸蛋白水解酶(caspase)抑制剂Z-VAD-FMK诱导细胞发生坏死性凋亡对人乳腺癌细胞MCF-7和MDA-MB-231增殖的影响。方法:体外培养MCF-7、MDA-MB-231细胞株。噻唑蓝(MTT)法检测2种细胞株空白对...     

Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'

Inflammatory breast cancer (IBC) is a rare but very aggressive form of breast cancer. Its definition is based on clinical criteria, but a molecular definition could be useful when data are incomplete or features are missing. Recently, the identification of overexpression of E-cadherin in IBC has improved understanding of the molecular basis of this disease. Consequently, the aim of this study was to try to determine an immunophenotypic 'signature' of IBC. A series of 80 cases of IBC were compared with 552 non-IBC control cases and a model was elaborated to evaluate the probability of an inflammatory carcinoma being present in any clinical situation. Tissue microarrays (TMAs) were used to determine the immunohistochemical profile of eight proteins including E-cadherin, EGFR, oestrogen and progesterone receptor (ER and PR), MIB1, ERBB2, MUC1, and P53. All the parameters tested were differentially expressed between IBC and control cases in univariate analysis (p < 0.001). The five variables that were significantly associated with IBC in multivariate analysis were E-cadherin > or = 300 [HR = 5.64 (2.92-10.87)], ER negative [HR = 3.00 (1.67-5.51)], MIB1 > 20 [HR = 3.54 (1.87-6.71)], MUC1 cytoplasmic staining [HR = 2.72 (1.49-4.96)], and ERBB2 positive 2+ or 3+ [HR = 2.46 (1.26-4.78)]. The probability that a breast cancer with this full phenotype at diagnosis was an IBC was 90.5%. If any one of the five parameters was missing, this probability dropped to 75% and was less than 50% when one, two, or three parameters were present. The 5-year overall survival (OS) and 5-year disease-free survival (DFS) of patients with IBC were not significantly different from those of the non-IBC control group that expressed four or five parameters (nIBC-1), but this nIBC-1 control group had a significantly worse outcome than the non-IBC control group (nIBC-2) with only 0-3 parameters (p = 0.0049 for OS and p < 0.0001 for DFS). In conclusion, an immunophenotypic signature was suggested for IBC. This could help to determine the worst cases, independent of clinical criteria.     

Long-Term Survival after High-Dose Chemotherapy Followed by Peripheral Stem Cell Rescue for High-Risk,Locally Advanced/Inflammatory,and Metastatic Breast Cancer

Patients with high-risk locally advanced/inflammatory and oligometastatic (≤3 sites) breast cancer frequently relapse or experience early progression. High-dose chemotherapy combined with peripheral stem cell rescue may prolong progression-free survival/relapse-free survival (PFS/RFS) and overall survival (OS). In this study, patients initiated high-dose chemotherapy with STAMP-V (carboplatin, thiotepa, and cyclophosphamide), ACT (doxorubicin, paclitaxel, and cyclophosphamide), or tandem melphalan and STAMP-V. Eighty-six patients were diagnosed with locally advanced/inflammatory (17 inflammatory) breast cancer, and 12 were diagnosed with oligometastatic breast cancer. Median follow-up was 84 months (range, 6-136 months) for patients with locally advanced cancer and 40 months (range, 24-62 months) for those with metastatic cancer. In the patients with locally advanced cancer, 5-year RFS and OS were 53% (95% CI, 41%-63%) and 71% (95% CI, 60%-80%), respectively, hormone receptors were positive in 74%, and HER2 overexpression was seen in 23%. In multivariate analysis, hormone receptor-positive disease and lower stage were associated with better 5-year RFS (60% for ER [estrogen receptor]/PR [progesterone receptor]-positive versus 30% for ER/PR-negative; P < .01) and OS (83% for ER/PR-positive versus 38% for ER/PR-negative; P?相似文献